Lanzamiento Intuniv. SHIRE

Intuniv® está indicado para el tratamiento del trastorno por déficit de atención e hiperactividad (TDAH) en niños y adolescentes de 6 a 17 años cuando los estimulantes no son adecuados, no se toleran o han mostrado ser ineficaces. Intuniv® se debe utilizar como parte...

Expert Recommendation: contributions to clinical practice of the new prodrug lisdexamfetamine dimesylate (LDX) in the treatment of attention deficit hyperactivity disorder (ADHD). Actas Esp Psiquiatr 2014

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurobiological disorders in childhood, and is characterized by inappropriate levels of inattention, hyperactivity and/or impulsiveness. The estimated prevalence in school children is 5.29%, and...